Navigation Links
Accera Announces Initiation of Clinical Trial for AC-1204

BROOMFIELD, Colo., Nov. 26, 2012 /PRNewswire/ -- Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).  AC-1204 is a formulation of caprylic triglyceride designed to improve cognitive function in mild to moderate Alzheimer's disease.

The study, (Titled: NOURISH AD), "A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects with Mild to Moderate Alzheimer's Disease (AD) with an Optional 26 Week Open-Label Extension," will examine the efficacy of 26 weeks daily administration of AC-1204 compared with placebo among participants diagnosed with mild-to-moderate AD. 

"With the recent investment we received from Nestlé Health Science, we're eager to generate additional clinical data illustrating the effectiveness of our product in patients with mild-to-moderate Alzheimer's disease," said Holger Kunze, president and CEO of Accera.  "We believe we have a truly innovative approach that will meet the needs of patients in this overwhelmingly underserved market." 

Accera's technology addresses the well-recognized physiological hallmark of the brain's inability to optimally metabolize glucose by providing an alternative energy source for brain cells.  In previous clinical trials, this approach has been shown to safely improve memory and cognitive function by inducing safe, therapeutic, tolerable and predictable levels of ketosis that improves memory in patients with mild-to-moderate AD.

The study will be a randomized, double-blind, placebo-controlled, parallel-group, multi-center trial.  It will be conducted at approximately 60 clinical sites in the US and is expected to enroll more than 400 patients.  This study will evaluate the effects of once daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilization, and quality of life among subjects with mild-to-moderate AD. 

The primary endpoint will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) after 26 weeks among both carriers and non carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4).  Previous studies demonstrated proof of concept for the company's unique approach. 

About Accera 
Accera, Inc. is a privately held commercial-stage healthcare company that developed and now markets Axona in the US.  Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases.  For more information about Accera, please visit www.accerapharma.comAccera, Inc.

Tiberend Strategic Advisors, Inc.(303) 999-3705

(212) 827-0020Bill Poncy

Andrew MielachVP Commercial Development

SOURCE Accera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
(Date:11/25/2015)... -- ARKRAY USA , Inc., a leader ... the accuracy of its blood glucose meter systems. Last ... and Cardiovascular Disease in Los Angeles ... 01 meter and the Assure ® Prism ... accurately measure glucose levels in blood is essential for ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... , ... Pixel Film Studios is back again with ProPanel: Pulse . ... endless. Users have full control over angle of view, speed method, start point, end ... to get heads to turn. , ProPanel: Pulse offers fully customizable pulsating shape masks, ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices ... show that delves into an array of issues that are presently affecting Americans. Dedicated ... open dialogue, this show is changing the subjects consumers focus on, one episode at ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):